BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US
Portfolio Pulse from
BeiGene's TEVIMBRA has been approved by the European Commission and is entering the EU market, having already reached the US market in October. This, along with BRUKINSA, is expected to drive BeiGene towards profitability within 12-18 months. Analysts project revenues of $4.64 billion next year, with a 12-month price target of $293/share, making it a strong buy.
December 01, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BeiGene's TEVIMBRA approval in the EU and US market entry is expected to significantly boost revenues, driving the company towards profitability within 12-18 months. Analysts have set a 12-month price target of $293/share, indicating a strong buy.
The approval of TEVIMBRA in the EU and its entry into the US market are key growth drivers for BeiGene. These developments are expected to significantly increase revenues, pushing the company towards profitability. Analysts' projections of $4.64 billion in revenue and a $293/share price target underscore the positive outlook, making it a strong buy.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100